China Medical System Holdings Ltd
SWB:2M7C
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
China Medical System Holdings Ltd
Cash Interest Paid
China Medical System Holdings Ltd
Cash Interest Paid Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Cash Interest Paid | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
C
|
China Medical System Holdings Ltd
SWB:2M7C
|
Cash Interest Paid
¥20.3m
|
CAGR 3-Years
-19%
|
CAGR 5-Years
-6%
|
CAGR 10-Years
-2%
|
|
|
Regencell Bioscience Holdings Ltd
NASDAQ:RGC
|
Cash Interest Paid
$0
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
G
|
Grand Pharmaceutical Group Ltd
HKEX:512
|
Cash Interest Paid
HK$169.1m
|
CAGR 3-Years
7%
|
CAGR 5-Years
8%
|
CAGR 10-Years
2%
|
|
|
Sino Biopharmaceutical Ltd
HKEX:1177
|
Cash Interest Paid
N/A
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
C
|
China Resources Pharmaceutical Group Ltd
HKEX:3320
|
Cash Interest Paid
HK$2B
|
CAGR 3-Years
1%
|
CAGR 5-Years
-5%
|
CAGR 10-Years
N/A
|
|
|
H
|
HUTCHMED (China) Ltd
HKEX:13
|
Cash Interest Paid
$2.5m
|
CAGR 3-Years
156%
|
CAGR 5-Years
25%
|
CAGR 10-Years
8%
|
|
China Medical System Holdings Ltd
Glance View
China Medical System Holdings Ltd., a prominent player in the pharmaceutical industry, weaves its business model around the intricate pathway of driving market expansion through innovation and strategic partnerships. Founded with a vision to bring cutting-edge and specialized medicines to the Chinese healthcare market, CMS has established itself as a stalwart distributor and marketer. The company operates by obtaining licenses and distribution rights for pharmaceutical products primarily from European and North American manufacturers. By leveraging these international partnerships, CMS effectively bridges the gap between Western innovation and Chinese demand, tailoring its portfolio to include niche and differentiated therapeutic products that cater to the evolving needs of China's healthcare landscape. At the core of CMS's revenue model lies its proficiency in brand building and market penetration. Unlike the conventional pharmaceutical giants focusing solely on R&D, CMS maximizes its profits through strategic marketing and efficient distribution networks. By prioritizing products that require expert promotion to healthcare professionals, CMS utilizes its extensive sales force to ensure these products gain maximum visibility and acceptance in the marketplace. This business model not only fosters a symbiotic relationship with international pharmaceutical partners but also sustains a robust pipeline of new offerings. Therefore, with a strategic balancing act between global pharmaceutical expertise and local market intricacies, China Medical System Holdings Ltd. continues to fortify its position as a pivotal conduit in the dissemination of specialized medical solutions across China.
See Also
What is China Medical System Holdings Ltd's Cash Interest Paid?
Cash Interest Paid
20.3m
CNY
Based on the financial report for Dec 31, 2025, China Medical System Holdings Ltd's Cash Interest Paid amounts to 20.3m CNY.
What is China Medical System Holdings Ltd's Cash Interest Paid growth rate?
Cash Interest Paid CAGR 10Y
-2%
Over the last year, the Cash Interest Paid growth was -47%. The average annual Cash Interest Paid growth rates for China Medical System Holdings Ltd have been -19% over the past three years , -6% over the past five years , and -2% over the past ten years .